{"id":500330,"date":"2020-08-04T13:16:02","date_gmt":"2020-08-04T13:16:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=500330"},"modified":"2020-08-04T13:16:02","modified_gmt":"2020-08-04T13:16:02","slug":"chronic-heart-failure-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-heart-failure-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_500330.html","title":{"rendered":"Chronic Heart Failure Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Heart Failure Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Chronic Heart Failure Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Chronic Heart Failure &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">(Albany, NY) Delveinsight has launched a new report on &#8220;<strong>Chronic Heart Failure &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8243;.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-heart-failure-market\" target=\"_blank\">Chronic Heart Failure &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/a>&#8220;<\/strong>&nbsp;report delivers an in-depth understanding of the Chronic Heart Failure, historical and forecasted epidemiology as well as the Chronic Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per the Delveinsight&rsquo;s analysis, the total diagnosed prevalent cases of Heart Failure in 7MM was found to be 12,026,384 in 2017.<\/li>\n<li>Among 7MM, US reported the highest number of prevalent cases of with 6,192,189 cases in 2017.<\/li>\n<li>According to DelveInsight, it is estimated that the Gender-specific prevalent cases of Heart Failure in France were 652,877 in males and 453,694 in females in 2017.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-market\">https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Chronic Heart Failure, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Chronic Heart Failure epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Heart Failure are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Chronic Heart Failure market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Heart Failure market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-heart-failure-market\" target=\"_blank\"><em><strong>Chronic heart failure<\/strong><\/em><\/a>, otherwise known as congestive heart failure or heart failure, is&nbsp;<strong>an ongoing inability of the heart to pump enough blood through the body to ensure a sufficient supply of oxygen.<\/strong>&nbsp;The causes of the condition vary, but some of the most common risk factors include old age,&nbsp;diabetes,&nbsp;high blood pressure&nbsp;and being overweight. Chronic heart failure is most common in men.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-market\">https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The most common symptoms of chronic heart failure include&nbsp;<strong>shortness of breath, tiredness, swelling of the legs and ankles, chest pain and a cough.<\/strong>&nbsp;It most commonly affects older people and people with other heart conditions and is typically treated with a combination of lifestyle and diet changes, and medications. Chronic heart failure is typically a long-term condition that gradually worsens over time. This is the feature that differentiates it from&nbsp;acute heart failure, which develops very suddenly. It cannot typically be cured, but symptoms can be managed effectively.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Top Company Profile Analysis in this Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis AG<\/li>\n<li>Bayer AG<\/li>\n<li>Orion Corp<\/li>\n<li>Vifor Pharma Ltd<\/li>\n<li>Cytokinetics Inc<\/li>\n<li>GlaxoSmithKline Plc<\/li>\n<li>Eli Lilly and Co<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-market\">https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table Of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Chronic Heart Failure<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Competitive Intelligence Analysis for Chronic Heart Failure<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Chronic Heart Failure: Market Overview at a Glance<\/strong><\/p>\n<p style=\"text-align: justify;\">4.1. Chronic Heart Failure Total Market Share (%) Distribution in 2017<\/p>\n<p style=\"text-align: justify;\">4.2. Chronic Heart Failure Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\"><strong>5. Chronic Heart Failure: Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p style=\"text-align: justify;\">5.2. Sign and Symptoms&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.3. Pathophysiology&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.4. Risk Factors&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.5. Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>6. Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Chronic Heart Failure Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.1. Chronic Heart Failure Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.4.1. Chronic Heart Failure Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.1.1. Chronic Heart Failure Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.2.1. Chronic Heart Failure Epidemiology Scenario in France (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.3.1. Chronic Heart Failure Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.4.1. Chronic Heart Failure Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.5.1. Chronic Heart Failure Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.6.1. Chronic Heart Failure Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><strong>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p style=\"text-align: justify;\">8.1. Chronic Heart Failure Treatment and Management<\/p>\n<p style=\"text-align: justify;\">8.2. Chronic Heart Failure Treatment Algorithm&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>9. Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Key Endpoints of Chronic Heart Failure Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Marketed Products<\/strong><\/p>\n<p style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>12. Emerging Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>13. Chronic Heart Failure: Seven Major Market Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p style=\"text-align: justify;\">13.2. Chronic Heart Failure Market Size in 7MM<\/p>\n<p style=\"text-align: justify;\">13.3. Chronic Heart Failure Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\"><strong>14. Attribute analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. 7MM: Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p style=\"text-align: justify;\">15.1.1. Chronic Heart Failure Total Market Size in the United States<\/p>\n<p style=\"text-align: justify;\">15.1.2. Chronic Heart Failure Market Size by Therapies in the United States<\/p>\n<p style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p style=\"text-align: justify;\">15.3.1. Chronic Heart Failure Total Market Size in Germany<\/p>\n<p style=\"text-align: justify;\">15.3.2. Chronic Heart Failure Market Size by Therapies in Germany<\/p>\n<p style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.1. Chronic Heart Failure Total Market Size in France<\/p>\n<p style=\"text-align: justify;\">15.4.2. Chronic Heart Failure Market Size by Therapies in France<\/p>\n<p style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p style=\"text-align: justify;\">15.5.1. Chronic Heart Failure Total Market Size in Italy<\/p>\n<p style=\"text-align: justify;\">15.5.2. Chronic Heart Failure Market Size by Therapies in Italy<\/p>\n<p style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p style=\"text-align: justify;\">15.6.1. Chronic Heart Failure Total Market Size in Spain<\/p>\n<p style=\"text-align: justify;\">15.6.2. Chronic Heart Failure Market Size by Therapies in Spain<\/p>\n<p style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p style=\"text-align: justify;\">15.7.1. Chronic Heart Failure Total Market Size in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">15.7.2. Chronic Heart Failure Market Size by Therapies in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p style=\"text-align: justify;\">15.8.2. Chronic Heart Failure Total Market Size in Japan<\/p>\n<p style=\"text-align: justify;\">15.8.3. Chronic Heart Failure Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><strong>16. Access and Reimbursement Overview of Chronic Heart Failure<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Market Drivers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Market Barriers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>21. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>23. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC:&nbsp;https:\/\/www.delveinsight.com\/sample-request\/chronic-heart-failure-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-heart-failure-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-heart-failure-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/chronic-heart-failure-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/chronic-heart-failure-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-heart-failure-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Chronic Heart Failure &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; &nbsp; (Albany, NY) Delveinsight has launched a new report on &#8220;Chronic Heart Failure &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8243;. &nbsp; DelveInsight&#8217;s &#8220;Chronic Heart Failure &#8211; Market Insights, Epidemiology, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-heart-failure-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_500330.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,413],"tags":[],"class_list":["post-500330","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/500330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=500330"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/500330\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=500330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=500330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=500330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}